Coherus Oncology Inc (CHRS) Q4 2024 Earnings Report

Coherus Oncology delivered a transitioning set of results in QQ4 2024 as it accelerates the strategic shift from ophthalmology and Humira biosimilars toward a fully integrated commercial-stage oncology company anchored by LOQTORZI in metastatic perlatform MPC and a growing PD-1 program. The company progressed on the UDENYCA divestiture (target closing late Q1/early Q2 2025), positioned LOQTORZI for NCCN-preferred status in MPC, and emphasized a high-potential pipeline (toripalimab backbone with casdozo CHS-114). In QQ4 2024, CHRS reported revenue of $54.1 million and a net loss of $50.7 million for the quarter, with full-year 2024 revenue around $267 million and a cash balance of $126 million. Management outlined a path to deleveraging through asset divestitures and a cash-rich close, while signaling meaningful long-term upside from LOQTORZI-led MPC leadership and pipeline catalysts through 2026 and beyond. The near-term financials reflect a high R&D/SG&A intensity and the non-cash and one-time effects of strategic restructuring; the operating and net losses are expected to compress meaningfully as the divestiture closes and the company pivots to higher-margin oncology growth. Investors should monitor (i) the UDENYCA transaction timing and regulatory close, (ii) LOQTORZI uptake and NCCN guidance adoption, (iii) pipeline readouts (casdozokitug/CHS-114 with toripalimab) and potential pivotal study signals, and (iv) the trajectory of debt reduction and free cash flow generation post-close.